Condition: Alzheimer Disease, Early Onset · Sponsor: Assistance Publique - Hôpitaux de Paris
Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency. French health authorities currently preconize a non-rug approach based on cognitive remediation or stimulation. The aim of this study is to compare the efficiency of the 2 approaches (non-drug versus donepezil) on the symptoms of Alzheimer's disease after 6 months of treatment.
This description comes directly from the study's public registry record.
DUMURGIER Julien, MD, PhD · +33140054313 · julien.dumurgier@aphp.fr
PAQUET Claire, MD, PhD · claire.paquet@inserm.fr
Always discuss trial participation with your own doctor first.
| Cognitive Neurology Center | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04661280